Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, First Section of TSE) announced that, effective August 17, 2021, its U.S. consolidated subsidiary Sunovion Pharmaceuticals Inc. (hereinafter, 'Sunovion') has signed an agreement on the transfer of all the shares of its whollyowned direct subsidiary, Sunovion Pharmaceuticals Europe Ltd. (hereinafter, 'SPE'), to a special purpose acquisition company ultimately controlled by Inflexion Private Equity Partners LLP (Head Office: London, U.K.; hereinafter, 'Inflexion') and the share transfer has been completed as of the same date.

Reasons for the share transfer SPE began marketing LATUDA, an atypical antipsychotic that has been a mainstay among products of the Sumitomo Dainippon Pharma Group, in Europe in 2014. After a comprehensive evaluation of SPE's current operational status and future business opportunities, a decision has been made to transfer all the shares of SPE to Inflexion. Sumitomo Dainippon Pharma and SPE have signed a license and supply agreement for LATUDA in Europe, which allows Inflexion to leverage SPE's business infrastructure and employees to continuously market LATUDA in Europe. Sumitomo Dainippon Pharma Group will continue to pursue its global strategy, which focuses on direct sales in the markets of Japan, North America, and China and other Asian countries, while maximizing growth in collaboration with partners in Europe and other regions.

Contact:

Corporate Communications

Sumitomo Dainippon Pharma Co., Ltd.

Osaka

TEL: +81-6-6203-1407

Tokyo

T: +81-3-5159-3300

(C) 2021 Electronic News Publishing, source ENP Newswire